Search PubMedSearch

Biomedical subjects

D Murphy

Publications and source records attributed to D Murphy.

At least 55 records · Page 3Linked to original sources

Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity.

Damnacanthal, an anthraquinone isolated from a plant extract, was found to be a potent, selective inhibitor of p56lck tyrosine kinase activity. The structure, potency, and selectivity of damnacanthal were confirmed by independent synthesis and testing. Damnacanthal exhibited an IC50 of 17 nM for inhibition of p56lck autophosphorylation and an IC50 of 620 nM for phosphorylation of an exogenous peptide by p56lck. Damnacanthal had > 100-fold selectivity for p56lck over the serine/threonine kinases, protein kinase A and protein kinase C, and > 40-fold selectivity for p56lck over four receptor tyrosine kinases. It also demonstrated modest (7-20-fold), but highly statistically significant, selectivity for p56lck over the homologous enzymes p60src and p59fyn. Mechanistic studies demonstrated that damnacanthal was competitive with the peptide binding site, but mixed noncompetitive with the ATP site. Although damnacanthal contains a potentially reactive aldehyde moiety, equilibrium dialysis experiments demonstrated that significant amine formation between damnacanthal and amines occurred only at high concentrations of reactants. However, damnacanthal appeared to bind nonspecifically to membrane lipids and was not active in whole cell tyrosine kinase assays. Damnacanthal is the most potent, selective inhibitor of p56lck tyrosine kinase activity described to date and may represent the starting point for the identification of novel, selective inhibitors of p56lck which are active in whole cell as well as in cell-free systems.

Alkaloids

Thymic vasopressin (AVP) transgene expression in rats: a model for the study of thymic AVP hyper-expression in T cell differentiation.

The peptide arginine vasopressin (AVP) is present within tissues of the immune system and has been implicated in T cell differentiation. We have investigated the expression and production of AVP in the thymus of rats which carry a rat AVP transgene. A 100% increase in thymic AVP immunoreactivity (ir) was detected in transgenic (TG) animals compared to age-matched wild-type (WT) controls. When tissues from TG and WT thymuses were subjected to reversed-phase high-performance liquid chromatography, ir-AVP eluted as a single peak which co-eluted with the standard. Immunocytochemical staining identified the presence of AVP in large epithelial cells within the thymic cortex in both WT and TG animals. The AVP precursor product neurophysin was also detected in epithelial cells in WT and TG thymuses. In situ hybridisation histochemistry using a probe specific for transgenic AVP mRNA revealed that the AVP transgene was expressed in TG thymic cells with a similar morphology and distribution to those which expressed endogenous AVP peptide in WT animals. These results demonstrate that the cellular location and immunoreactive form of AVP expressed in TG animals are similar to that found in WT controls. Thus the TG rat appears to be a model of true physiological, rather than ectopic, over-expression of AVP in the thymus. The hyper-expression of AVP in the thymic epithelial cells of TG animals provides a model in which can be studied the influence of AVP on T cell development and differentiation within the thymus.

Animals

Steroid versus placebo injection for trigger finger.

The ability of a single injection of steroid and lidocaine to bring about cure of primary trigger finger was determined and compared with a control placebo injection of only lidocaine. Twenty-four patients were randomized to the therapeutic or control group and were followed prospectively. One physician administered the injection, another the clinical examination after injection, and a third evaluated the results blindly. Patients were not told to which group they were assigned. Nine of the 14 patients in the steroid group versus two of the ten patients in the placebo group were cured of trigger finger at final follow-up examination. After injection, seven patients had immediate but temporary relief of triggering because of flexor sheath distention. One injection cured 64% [corrected] of patients with primary trigger finger with no side effect and is the recommended nonsurgical treatment.

Administration, Topical

Subjective assessment of allergy relief following group hypnosis and self-hypnosis: a preliminary study.

Self-hypnosis was taught to 34 self-identified allergy patients who attended two training classes. They practiced on their own and were questioned two months later. Seventy-six percent of the subjects reported they felt an improvement in their symptoms; 86% of those who were medicated decreased their medicines. Practice was clearly related to reported improvement. "Feeling hypnotized" was not related to improvement.

Adolescent

Acute respiratory failure mediated by reactive drug metabolites.

Reactive drug metabolites have been implicated in the pathogenesis of adverse reactions to the aromatic anticonvulsants. A patient presented with a hypersensitivity reaction to the aromatic anticonvulsants which evolved into Stevens-Johnson syndrome and was complicated by the presence of adult respiratory distress syndrome. When the patient's cells were tested for sensitivity in vitro to reactive metabolites of the aromatic anticonvulsants, they were markedly more sensitive to metabolites of the aromatic anticonvulsants than were the cells of controls (p < 0.05). The adult respiratory distress syndrome has not previously been described as a complication of hypersensitivity reactions to the aromatic anticonvulsants. In vitro testing also demonstrated cross-sensitivity to the anticonvulsants, allowing selection of a therapeutic regimen which would not be associated with a risk of exacerbating the hypersensitivity reaction.

Carbamazepine

Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.

BACKGROUND AND PURPOSE: CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke. METHODS: At each dose level, 6 patients were randomized to one or two intravenous bolus doses of CGS 19755, and 2 patients were randomized to placebo. An unblinded safety and monitoring committee-evaluated results at each dose before ascending to the next level. All patients at the first level (1 mg/kg) received two doses separated by 12 hours. The first 2 patients at 2 mg/kg received two doses, but adverse experiences occurred in both; subsequent patient groups received single doses of 2.0, 1.75, or 1.5 mg/kg. RESULTS: Adverse experiences (agitation, hallucinations, confusion, paranoia, and delirium) occurred in all 6 patients treated with 2 mg/kg, and in 3 of 5 at 1.75 mg/kg. Similar but milder adverse experiences were noted in 4 of 7 patients at 1.5 mg/kg and 1 of 6 patients at 1.0 mg/kg. Adverse experiences began between 20 minutes and 22 hours (mean, 8 hours) after treatment and lasted 2 to 60 hours (mean, 24 hours). Mortality was 1 of 8 in patients receiving placebo and 3 of 24 in treated patients. In treated survivors, median and mean percent improvement in National Institutes of Health Stroke Scale scores from baseline to terminal visit (mean, 86 days) was comparable at all doses, and 95% of treated patients had Barthel Index scores of > or = 70 at the terminal visit. CONCLUSIONS: We conclude that a single intravenous dose of 1.5 mg/kg CGS 19755 is safe and tolerable in patients with acute ischemic stroke. An efficacy trial is indicated.

Acute Disease

Antibodies to canine granulocyte colony-stimulating factor induce persistent neutropenia.

A severe persistent neutropenia developed in a rabbit that was injected intradermally with 120, 60, 60, and 120 micrograms of recombinant canine granulocyte colony-stimulating factor (cG-CSF) on days 1, 22, 31, and 44, respectively. The neutropenia was present from day 44 to day 205. The nadir of the neutropenia (60 cells/microliters) occurred in conjunction with peak antibody titer (640,000) to cG-CSF on day 58. The immune antiserum from this rabbit reacted positively for cG-CSF on Western blot analysis. The immune antiserum also neutralized the activity of cG-CSF. On day 160, examination of the bone marrow showed marked granulocytic hypoplasia and mild erythroid hyperplasia. On day 205, the rabbit was still neutropenic (430 cells/microliters), even though the last injection of cG-CSF was given 161 previously. Necropsy on day 205 showed that there was still mild granulocytic hypoplasia with mild erythroid hyperplasia. Because of the lack of any inflammatory foci found at necropsy and the granulocytic hypoplasia, it was thought that the neutropenia was most likely due to decreased production and was not a consumptive process. It is hypothesized that the antibody that was produced to cG-CSF neutralized the effect of endogenous rabbit granulocyte colony-stimulating factor and prevented the normal proliferation and maturation of the rabbit neutrophils.

Animals

Notoedric mange in the Florida panther (Felis concolor coryi).

Notoedric mange (Notoedres cati) was found in a neonate Florida panther (Felis concolor coryi) and presumably its mother on 22 June 1992 and 8 February 1993, respectively, in Collier County, Florida (USA). Both infestations were treated successfully with 0.2 mg/kg ivermectin. This is the first known case of notoedric mange in the endangered Florida panther.

Animals

Oxytocin transgenic mice.

We have compared the expression patterns in transgenic mice of bovine oxytocin constructs consisting of the 0.9 kilobase pair (kbp) structural gene flanked by varying lengths of upstream and downstream sequences. Over 200 offspring were derived from fertilized one-cell mouse eggs injected with construct bOT6.5, which consists of 3 kbp of upstream sequences and 2.6 kbp of downstream sequences. However, no transgenic founders were identified. In parallel experiments with other constructs, 30% of pups carried integrated copies of the injected transgene DNA. It therefore appears that bOT6.5 is toxic to mouse embryos. As previously reported (Ang et al., 1991), bOT, consisting of 2.6 kbp of downstream sequences and 0.6 kbp of upstream sequences, was expressed in lung and in testicular Sertoli cells, but no expression was detected in the hypothalamus. bOT3.5, which consists of 0.6 kbp of upstream sequences and 1.9 kbp of downstream sequences, retains testis and lung expression, but, surprisingly, is also expressed in the hypothalamus. These data suggest that the 0.7 kbp of downstream sequences that are present in bOT, but which are absent from bOT3.5, contain elements that mediate the repression of hypothalamic expression. The activity of this repressor must be itself overcome in the normal genomic context of the bovine OT gene. Within the hypothalamus, in situ hybridisation analysis has revealed expression of bOT3.5 in the supraoptic nucleus (SON) and paraventricular nucleus (PVN), but not in the suprachiasmatic nucleus (SCN). In parallel with the response of the endogenous murine OT RNA, 7 days of salt-loading resulted in a significant increase in the level of transgene RNA in the SON. In the PVN, neither the endogenous OT RNA nor the transgene RNA responded significantly to salt-loading. Transgene RNA levels in the hypothalamus have also been shown to be elevated during late pregnancy and lactation.

Animals

Ectopic vasopressin expression in MMTV-Wnt-1 transgenic mice modifies mammary tumor differentiation and pathology.

A transgenic mouse model has been developed to test the involvement of ectopic neuropeptide production as a secondary factor in cancer. Mice bearing a mouse mammary tumor virus-vasopressin (MMTV-VP) fusion transgene synthesized authentic vasopressin in mammary ducts and alveoli, but this had no effect on mammary gland development and growth. Mice bearing the MMTV-VP transgene were then mated with mice bearing the MMTV-Wnt-1 transgene to produce bitransgenic animals. Two types of mammary tumor develop in MMTV-Wnt-1 mice; type A mammary adenocarcinomas are uniform with fine acinar structure composed of small epithelial cells arranged to form round cavities and elongated tubules, while adenocarcinoma type B tumors have acinar areas, cystic spaces filled with blood or fluid, intracystic papillary projections, and cords as well as sheets of cells. Compared to the MMTV-Wnt-1 mice, the bitransgenic animals developed proportionally less type B tumors. Further, type B mammary adenocarcinomas from bitransgenic mice exhibited increased proliferation and growth, as judged by mitotic index and argyrophilic nucleolar organizer region counts, compared to type B tumors from MMTV-Wnt-1 mice. These data provide evidence that ectopic neuropeptide production can modulate the development of tumors in vivo.

Adenocarcinoma

A testis-specific promoter in the rat vasopressin gene.

In the rat testis, the vasopressin gene is transcribed into precursor RNAs that are processed into a number of mature transcripts. One of these transcripts has a structure identical to that of the hypothalamic RNA that encodes the vasopressin prepropeptide, but is present at such low levels that it can only be detected by the polymerase chain reaction. Other vasopressin-like RNAs are derived from differential splicing events that join transcribed sequences between 3 and 9 kilobases upstream of the hypothalamic transcription start site to exons corresponding to II and III of the hypothalamic-type RNA. Here we describe the sequence of a testis-specific promoter and the exon structure of its transcription unit. We show that an in vitro synthesized RNA corresponding to the longer testicular vasopressin gene-derived transcript is not able to act as a template for protein synthesis in two different cell-free lysates. As attempts to localize the vasopressin-gene derived RNAs to particular cell types in the testis by in situ hybridization have consistently failed, we have used indirect methods. Three different procedures were used to effect germ cell depletion in adult male rats. Acute heat treatment of the testis, chronic ingestion of hydroxyurea, and chronic vitamin A deficiency all reduced the level of the aberrant testicular vasopressin-gene derived RNAs, indicating that their expression is closely associated with the integrity of germ cells and ongoing spermatogenesis.

Animals

A human cDNA coding for the Leydig insulin-like peptide (Ley I-L).

cDNA clones for the human Leydig insulin-like peptide (Ley I-L) have been isolated and characterized. The nucleotide sequence of the 743-bp cDNA includes an incomplete 7-bp 5'-noncoding region, an open reading frame of 393 bp, and a 343-bp 3'-noncoding region. By primer extension analysis, the transcription start site was determined as being 14-bp upstream of the translation start site. The underlying gene is expressed in the testis but not in other organs. From the cDNA sequence, it can be deduced that the Ley I-L protein is synthesized as a 131-amino-acid (aa) preproprotein and that it contains a 24-aa signal peptide. Comparison of the pro Ley I-L protein with members of the insulin-like hormone superfamily predicts that the biologically active hormone, after proteolytic processing of the C peptide, consists of a 31-aa long B chain and a 26-aa long A chain, and that it has a molecular weight of 6.25 kDa.

Amino Acid Sequence

Quantitative analysis of the surface morphology and textile structure of the polyurethane Vascugraft arterial prosthesis using image and statistical analyses.

The surface morphology and textile structure of the Vascugraft polyurethane arterial prosthesis were investigated. Novel methods of image analysis and the presentation of statistical data were used to obtain quantitative results of the surface morphology of the non-woven microfibrous structure of prostheses of three different sizes. These techniques have identified apparent differences in the distributions of thickness and orientation of the microfibres between the internal and external surfaces and between the three prostheses investigated.

Biocompatible Materials

Audit of complete axillary dissection in early breast cancer.

The role of complete axillary dissection (CAD) in the management of breast cancer is controversial and largely unresolved. Acceptance of the results of trials incorporating CAD assumes that the axillary dissection is truly complete. To address this point, and also to define quality control criteria for this operation within our unit, we audited 100 consecutive axillary dissections as follows: the primary surgeon performed what he/she felt to be a thorough CAD and submitted separately the contents of level I, II and III for pathological evaluation; a second surgeon then independently assessed the dissection and arbitrarily labelled any further excised tissue as level IV. Level IV nodes were retrieved in 38% of cases. Tumour involvement of level IV nodes was noted in 5% (2/38) of dissections where lymph nodes were retrieved, but in neither instance was pathological staging altered. There was a significant decrease in the incidence of level IV node retrieval from 47% (28/60) in the first 6 months of audit to 20% (8/40) subsequently. This novel approach to our continuing audit identified quality control criteria for this procedure in our unit and suggested that audit of this kind benefits training.

Breast Neoplasms

Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features.

Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.

Base Sequence